Ardent Health Partners, Inc. (ARDT) AI Stock Analysis

• Market Cap: $1.26B
• Dividend Yield: N/A
• Average Volume (3M): 407.60K
• Price to Earnings (P/E): 6.1
• Beta (1Y): 0.50
• Revenue Growth: 10.86%
• EPS Growth: 125.05%
• Country: US
• Employees: 19,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.17
• Shares Outstanding: 143,187,680
• 10 Day Avg. Volume: 333,763
• 30 Day Avg. Volume: 407,603
• PEG Ratio: 0.03
• Price to Book (P/B): 2.00
• Price to Sales (P/S): 0.38
• P/FCF Ratio: 17.74
• Enterprise Value/Market Cap: 3.22
• Enterprise Value/Revenue: 0.64
• Enterprise Value/Gross Profit: 0.91
• Enterprise Value/Ebitda: 7.34
• 1Y Price Target: $13.96
• Price Target Upside: 57.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: $9.00 ▲(1.47% Upside)

Ardent Health Partners, Inc. demonstrates strong financial performance and valuation, with significant growth in revenue and EBITDA. However, technical indicators show bearish momentum, and cost pressures remain a challenge. The company's strategic initiatives for cost optimization and growth provide a positive outlook.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for services and effective market positioning, supporting long-term business expansion.

Cash Flow Improvement

Improved cash flow enhances financial flexibility, enabling strategic investments and debt reduction, contributing to long-term stability.

IMPACT Program

The IMPACT program's cost optimization initiatives will enhance operational efficiency, supporting margin expansion and sustainable growth.

Negative Factors

High Debt Levels

High leverage can limit financial flexibility and increase risk, potentially impacting long-term financial health and investment capacity.

Cost Pressures

Rising costs, especially in professional fees, can compress margins and hinder profitability, challenging long-term financial performance.

Revised EBITDA Guidance

Lower EBITDA guidance reflects ongoing financial challenges, potentially affecting investor confidence and strategic growth initiatives.

Ardent Health Partners, Inc. Business Overview & Revenue Model

Company Description

Ardent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, LLC is a subsidiary of EGI-AM Investments, L.L.C.

How the Company Makes Money

Ardent Health Partners generates revenue primarily through patient services, which include hospital admissions, outpatient procedures, and specialty care services. The company bills patients and their insurance providers for services rendered, with revenue derived from both private insurance and government programs such as Medicare and Medicaid. Key revenue streams include inpatient services, outpatient services, diagnostic imaging, and surgical services. Additionally, Ardent may engage in partnerships with insurance companies and other healthcare organizations, allowing it to expand its service offerings and enhance its revenue opportunities. The company also focuses on operational efficiency and patient volume growth to increase its profitability.

Ardent Health Partners, Inc. Financial Statement Overview

Summary

Ardent Health Partners, Inc. shows strong revenue and cash flow growth, with a solid gross profit margin. However, the net profit margin and high debt-to-equity ratio indicate areas for improvement. Overall, the company exhibits potential for stability and growth.

Income Statement

Ardent Health Partners, Inc. shows a solid revenue growth rate of 2.05% TTM, indicating a positive trajectory in revenue generation. The gross profit margin of 64.11% TTM is strong, reflecting efficient cost management. However, the net profit margin of 3.24% TTM is relatively low, suggesting room for improvement in profitability. EBIT and EBITDA margins are moderate at 6.39% and 8.89% TTM, respectively, indicating stable operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has improved to 1.84 TTM from previous years, showing a reduction in leverage, but it remains relatively high, indicating potential financial risk. The return on equity (ROE) of 17.09% TTM is healthy, suggesting effective utilization of shareholder equity. However, the equity ratio of 24.02% TTM indicates a lower proportion of equity financing, which could be a concern for financial stability.

Cash Flow

Ardent Health Partners, Inc. demonstrates a strong free cash flow growth rate of 43.24% TTM, highlighting improved cash generation capabilities. The operating cash flow to net income ratio of 0.39 TTM and free cash flow to net income ratio of 0.43 TTM suggest a moderate conversion of income into cash, indicating decent cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2018	Dec 2017
Income Statement
Total Revenue	6.33B	5.97B	5.41B	5.13B	4.16B	3.00B
Gross Profit	4.47B	4.93B	5.27B	4.17B	4.16B	3.00B
EBITDA	551.64M	574.93M	350.00M	531.70M	281.84M	230.91M
Net Income	205.06M	210.34M	50.29M	188.91M	-143.02M	-35.65M
Balance Sheet
Total Assets	5.15B	4.96B	5.10B	4.86B	2.75B	2.37B
Cash, Cash Equivalents and Short-Term Investments	609.44M	556.78M	437.58M	456.12M	59.66M	71.96M
Total Debt	2.28B	2.28B	2.40B	2.39B	1.26B	952.69M
Total Liabilities	3.52B	3.43B	4.02B	3.81B	2.03B	1.61B
Stockholders Equity	1.24B	1.13B	670.90M	639.05M	331.64M	377.72M
Cash Flow
Free Cash Flow	154.89M	127.52M	84.29M	-189.47M	-1.07M	-2.06M
Operating Cash Flow	364.07M	315.03M	221.70M	-38.36M	159.59M	119.47M
Investing Cash Flow	-233.44M	-220.46M	-137.98M	46.58M	-525.11M	-983.27M
Financing Cash Flow	-84.33M	24.64M	-102.26M	-270.33M	353.22M	843.15M

Ardent Health Partners, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDT, the sentiment is Negative. The current price of 8.87 is below the 20-day moving average (MA) of 10.17, below the 50-day MA of 12.67, and below the 200-day MA of 13.05, indicating a bearish trend. The MACD of -1.27 indicates Negative momentum. The RSI at 26.25 is Positive, neither overbought nor oversold. The STOCH value of 52.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARDT.

Ardent Health Partners, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	72 Outperform	$2.12B	21.24	9.94%	1.83%	23.74%	-18.99%
SEM	69 Neutral	$1.66B	15.35	5.57%	1.63%	-22.96%	-59.35%
ARDT	67 Neutral	$1.26B	6.09	25.56%	―	10.86%	125.05%
ACHC	62 Neutral	$1.35B	12.42	3.49%	―	4.58%	-61.50%
BKD	57 Neutral	$2.53B	―	-214.33%	―	3.93%	-42.22%
AVAH	56 Neutral	$1.91B	25.38	―	―	15.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Ardent Health Partners, Inc. Corporate Events

Ardent Health Reports Q3 2025 Financial Results

Ardent Health Partners, Inc. is a prominent healthcare provider operating in mid-sized urban communities across the United States, focusing on delivering accessible and innovative healthcare services through a network of hospitals and care sites.

Ardent Health Partners Reports Strong Q3 Amid Cost Challenges

Ardent Health Partners, Inc. recently held its third-quarter earnings call, which revealed a mixed sentiment. The company reported strong revenue and EBITDA growth, driven by robust demand in key markets. However, persistent cost pressures, particularly from professional fees and payer denials, have led to a revision in EBITDA guidance. Despite these challenges, the company’s IMPACT program is seen as a positive step towards cost optimization, although industry headwinds continue to pose a challenge.

Ardent Health Partners Amends Credit Agreements for Flexibility

On September 18, 2025, Ardent Health, Inc., along with its subsidiary AHP Health Partners, Inc., and other related parties, entered into significant amendments to their existing credit agreements with Bank of America and other financial institutions. The amendments included refinancing outstanding term loans, extending the maturity date to September 18, 2032, reducing interest rates by 50 basis points, and updating certain financial covenants. These changes are expected to improve the company’s financial flexibility and reduce borrowing costs.

The most recent analyst rating on (ARDT) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Ardent Health Partners, Inc. stock, see the ARDT Stock Forecast page.